- Home
- EDTK vs GDTC Comparison
EDTK vs GDTC Comparison
Compare EDTK & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDTK | GDTC |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | China | Singapore |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDTK | GDTC |
|---|---|---|
| Price | $1.00 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.7K | ★ 27.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.73 |
| 52 Week High | $1.18 | $3.68 |
Technical Indicators
Market Signals| Indicator | EDTK | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 62.36 | 44.40 |
| Support Level | $0.95 | $0.96 |
| Resistance Level | $1.06 | $1.25 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 87.50 | 43.53 |
Price Performance
Historical ComparisonAbout EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.